Contrasting Mesoblast (NASDAQ:MESO) and Titan Pharmaceuticals (NASDAQ:TTNP) – Riverton Roll

Mesoblast (NASDAQ:MESO) and Titan Pharmaceuticals (NASDAQ:TTNP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends and profitability.

Profitability

This table compares Mesoblast and Titan Pharmaceuticals net margins, return on equity and return on assets.

Volatility & Risk

Mesoblast has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500. Comparatively, Titan Pharmaceuticals has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Mesoblast and Titan Pharmaceuticals, as provided by MarketBeat.

Mesoblast currently has a consensus price target of $12.83, indicating a potential upside of 28.21%. Titan Pharmaceuticals has a consensus price target of $1.00, indicating a potential upside of 274.67%. Given Titan Pharmaceuticals stronger consensus rating and higher probable upside, analysts plainly believe Titan Pharmaceuticals is more favorable than Mesoblast.

Insider and Institutional Ownership

2.7% of Mesoblast shares are held by institutional investors. Comparatively, 1.5% of Titan Pharmaceuticals shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 2.0% of Titan Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Mesoblast and Titan Pharmaceuticals top-line revenue, earnings per share (EPS) and valuation.

Titan Pharmaceuticals has lower revenue, but higher earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Titan Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Mesoblast beats Titan Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Mesoblast Company Profile

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.

See original here:
Contrasting Mesoblast (NASDAQ:MESO) and Titan Pharmaceuticals (NASDAQ:TTNP) - Riverton Roll